Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Money Morning13d
Eli Lilly Faces ‘Death Cross’ Selloff: This is the Stock's Next Target Price...
The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...
The Motley Fool7d
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
Shares of pharmaceutical giant Eli Lilly have been falling in recent months. The company updated its guidance last week, and investors weren't impressed. It could be a tough year for Eli Lilly ...
Nasdaq14d
Eli Lilly's Options: A Look at What the Big Money is Thinking
Deep-pocketed investors have adopted a bearish approach towards Eli Lilly (NYSE:LLY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...